Navigation Links
Cellular Dynamics Announces Commercial Launch of iCell® Neurons for Neuroscience Drug Discovery
Date:12/13/2011

MADISON, Wis., Dec 13, 2011 /PRNewswire/ -- Cellular Dynamics International (CDI) today announced the commercial launch of human iCell® Neurons for use in neuroscience drug discovery, neurotoxicity screens, and other health research. This is the first commercial availability of human neurons, or brain cells, created from induced pluripotent stem (iPS) cells in the quantity, quality, and purity required for life science research.

iCell Neurons exhibit the typical physiological characteristics and responses of the neurons with which we are born. These neurons quickly form connective neuronal networks that are electrophysiologically active, making them useful in a variety of applications commonly used in neuroscience research, including cell viability, ATP production, oxidative stress, neurite outgrowth, electrophysiology, and synaptic neurotransmission assays. CDI's proprietary manufacturing capabilities enable the production of iCell Neurons in industrial quantities with greater than 95% purity.

CDI has successfully engaged in pre-launch collaborations with several pharmaceutical customers for validation testing and establishing disease-relevant neuroscience assays. "We have been working with CDI for some time now and are very impressed with their iCell Neurons, which provide us with a unique model of pure and highly differentiated human neurons showing real potential for measuring functional neurotransmission," said Dr. Pascal Laeng, Head of Molecular and Cellular Pharmacology at Galenea Corp. "The preliminary data are very promising, and we look forward to continued collaboration with CDI to implement iCell Neurons in our high throughput assay of synaptic function."

Dr. Johannes Mosbacher, Director of CNS Electrophysiology, Actelion Pharmaceuticals, said, "CDI's human iPSC-derived neurons, iCell Neurons, offer unprecedented opportunities for drug discovery and development. The cells not only functionally express key ion channels and receptors but also form electrophysiologically active networks. These attributes of iCell Neurons help substantiate the possibility that these cells provide an exciting new human model of neuronal physiology that augments traditional ones, such as rat primary neurons and human neuronal cell lines."

iCell Neurons present a human platform that enables the modeling of healthy neuronal cells to improve the predictability of drug candidate efficacy and toxicity screens early in the pharmaceutical pipeline process. "The human brain represents a complex organ that has consistently proven difficult to model in vitro, and this is partially reflected in the lack of effective therapeutics to treat neurological diseases and disorders," said Chris Parker, Chief Commercial Officer. "Degenerative diseases, such as Alzheimer's, Parkinson's, and ALS, and genetic dispositions, such as Huntington's and muscular dystrophy, can also be modeled to better understand these disease states for drug discovery and eventual therapies."

Because iCell Neurons are human cells, they better recapitulate human biology. These cells are better predictors of drug candidate responses than current cell models, including immortalized cell lines and primary neurons isolated from rodent tissues, which present significant limitations in biological relevance, reproducibility, and scalability. 

Robert Palay, Chief Executive Officer of CDI, said, "iCell Neurons are the third iPSC-derived product CDI has now commercially launched. We launched the first product ever developed from iPS cells, iCell Cardiomyocytes, in December 2009, followed by iCell Endothelial Cells in September 2011. Based on strong intellectual property and exclusively licensed patents, we have developed a proprietary process to industrialize the manufacture of virtually any cell type in the human body. CDI is the first company to utilize stem cell technology to manufacture the vast quantities of high quality stem cells and tissue cells required to better understand human biology, revolutionize the drug discovery process, and develop cell-based therapies to treat human diseases."

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development, cell therapy, tissue engineering and organ regeneration. CDI harnesses its unique manufacturing technology to produce differentiated tissue cells from any individual's stem cell line in industrial quality, quantity and purity. CDI is accelerating the adoption of pluripotent stem cell technology, adapting its methods to fit into standard clinical practice by the creation of individual stem cell lines from a standard blood draw. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human pluripotent stem cell research at the University of Wisconsin-Madison. CDI's facilities are located in Madison, Wisconsin. See www.cellulardynamics.com.


'/>"/>
SOURCE Cellular Dynamics International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Assays & Cellular Targets Conference, Booth 11
2. MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting
3. Orange and Medic4all Launched the Worlds First Cellular Tele-Health Service
4. Intra-Cellular Therapies Reports Positive Final Results of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
5. MIT, BU engineer cellular circuits that count events
6. New Cellular Bioenergetics Workshops Series Inaugurated by Seahorse Bioscience with Two of the Worlds Leading Bioenergetics Researchers
7. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
8. iZumi Bio and Pierian Merge to Form iPierian to Advance Cellular Reprogramming
9. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
10. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
11. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports the ... Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over the ... Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. , ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing and ... clear demand for Microsoft Azure from major institutions collecting and analyzing genomic data,” ...
(Date:2/10/2016)... ... ... Cenna Bioscience Inc., an emerging biopharmaceutical company focused on the discovery and ... been selected to present at the Cavendish Global Health Impact Forum taking place February ... of the Forum is to help family offices and foundations develop and implement their ...
(Date:2/9/2016)... ... ... With a presidential election in November and the future of U.S. healthcare in ... top healthcare leaders for a night and day of debates and discussions about what ... the University of Pennsylvania’s Wharton School, will be held February 18 – 19, 2016 ...
Breaking Biology Technology:
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
Breaking Biology News(10 mins):